Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Carfilzomib/cyclophosphamide/dexamethasone

Various toxicities: 6 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Shank BR, et al. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clinical Lymphoma, Myeloma & Leukemia 23 : 279-290, No. 4, 2023. Available from: URL: http://doi.org/10.1016/j.clml.2022.12.004 Shank BR, et al. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clinical Lymphoma, Myeloma & Leukemia 23 : 279-290, No. 4, 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​clml.​2022.​12.​004
Metadaten
Titel
Carfilzomib/cyclophosphamide/dexamethasone
Various toxicities: 6 case reports
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47835-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Gemcitabine

Case report

Darbepoetin-alfa

Case report

Methotrexate

Case report

Atezolizumab

Case report

Rituximab